Get started
Author

Ivan V. Grishagin

Observed name: Ivan Grishagin
ORCID: 0000-0003-2985-4336
Observed ORCID: 0000-0003-2985-4336
OpenAlex ID: A5050479220
The NCATS BioPlanet – An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics
2019 · Ruili Huang, Ivan Grishagin, et al. · Frontiers in Pharmacology · 294
PDF
Automatic cell counting with ImageJ
2014 · Ivan V. Grishagin · Analytical Biochemistry · 234
Lung Fibrosis after COVID-19: Treatment Prospects
2021 · Evgeny Bazdyrev, Polina Rusina, et al. · Pharmaceuticals · 192
PDF
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors
2024 · Sanju Sinha, Rahulsimham Vegesna, et al. · Nature Cancer · 118
PDF
In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics
2014 · Brooke Bullock Lao, Ivan Grishagin, et al. · Proceedings of the National Academy of Sciences · 112
PDF
In vivo anticancer activity of rhomboidal Pt(II) metallacycles
2014 · Ivan V. Grishagin, J. Bryant Pollock, et al. · Proceedings of the National Academy of Sciences · 105
PDF
NCATS Inxight Drugs: a comprehensive and curated portal for translational research
2021 · Vishal B Siramshetty, Ivan Grishagin, et al. · Nucleic Acids Research · 55
An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD)
2020 · Qian Zhu, Dac-Trung Nguyen, et al. · Journal of Biomedical Semantics · 54
PDF
Mapping of UK Biobank clinical codes: Challenges and possible solutions
2022 · Oleg Stroganov, Alena Fedarovich, et al. · PLoS ONE · 28
PDF
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia
2022 · Evgeny Bazdyrev, Maria Panova, et al. · Pharmaceuticals · 19
PDF
Low-dose salinomycin induces anti-leukemic responses in AML and MLL
2016 · Gary D.R. Roulston, Charlotte L. Burt, et al. · Oncotarget · 16
PDF
A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research
2022 · Gergely Zahoránszky-Kőhalmi, Vishal B. Siramshetty, et al. · Journal of Chemical Information and Modeling · 9
Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.
2022 · Sanju SInha, Rahulsimham Vegesna, et al. · Journal of Clinical Oncology · 5
Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia
2019 · Laura M. Kettyle, Charles-Étienne Lebert-Ghali, et al. · Cancers · 5
PDF
High-Throughput Screen Identification of Albendazole As a Novel Repurposed Drug in Acute Myeloid Leukaemia
2017 · Kyle B. Matchett, Ivan Grishagin, et al. · Blood · 4
Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors
2022 · Sanju Sinha, Rahulsimham Vegesna, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Mebendazole: A candidate FDA approved drug for repurposing in leukaemia
2016 · Kyle B. Matchett, Ivan Grishagin, et al. · Research Portal (Queen's University Belfast) · 2
RouteWise – An Integration Friendly Platformfor Interactive Synthesis Routes
2025 · Ilia Vorontcov, Nathan Miller, et al. · ChemRxiv
PDF
Correction: Mapping of UK Biobank clinical codes: Challenges and possible solutions
2024 · Oleg Stroganov, Alena Fedarovich, et al. · PLoS ONE
PDF
AM4 - group work
2017 · Edoardo Paluan, Roman Gurinovich, et al.
Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance
2015 · Laura M Kettyle, Ivan Grishagin, et al. · Blood
Abstract 1014: Novel selective HIF1 alpha inhibitor: Well tolerated with excellent efficacy in renal cell cancer xenograft studies
2014 · Ramin Dubey, Ivan Grishagin, et al. · Cancer Research
Abstract 283: OOPs: Novel HIF-1α mimics
2012 · Ivan V. Grishagin, Bogdan Z. Olenyuk, et al. · Cancer Research
Works count: 23
Citation count: 1,255
H-index: 11
I10-index: 11
Year
Topic
Type